{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:47:17Z","timestamp":1793526437031,"version":"4.5.0"},"reference-count":16,"publisher":"American Association for Cancer Research (AACR)","issue":"1","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai | Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>E7389-LF is a liposomal formulation of eribulin that contributes to tumor vascular remodeling. The phase II part of this phase Ib\/II study assessed the efficacy\/safety of E7389-LF in combination with nivolumab in several disease cohorts; herein, we report results from the small cell lung cancer (SCLC) cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>Patients with unresectable\/measurable SCLC and disease progression with first-line platinum-based chemotherapy with\/without an immune checkpoint inhibitor (ICI) were enrolled to receive E7389-LF 2.1 mg\/m2 plus nivolumab 360 mg intravenously every 3 weeks. The primary objective of this part was to assess the objective response rate (ORR). Secondary objectives included assessments of safety and progression-free survival (PFS); exploratory assessments included overall survival (OS) and biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirty-four patients were enrolled. By the data cut-off date (May 31, 2022), 29 (85.3%) had discontinued. Efficacy\/biomarker analyses included 33 patients (1 had their diagnosis changed postenrollment); the ORR of E7389-LF plus nivolumab was 24.2% [95% confidence interval (CI): 11.1\u201342.3], the median PFS was 3.98 months (95% CI: 2.63\u20134.40), and, at a median follow-up of 10.6 months, the median OS was not reached (95% CI: not estimable). Notably, 27 of 33 patients (81.8%) had received an ICI as their prior first-line therapy. Treatment-related, treatment-emergent adverse events occurred in 97.1% (any grade) and 82.4% (grade \u22653) of enrolled patients; the most common event was neutropenia. Changes in vascular and immune-related plasma markers were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>E7389-LF 2.1 mg\/m2 in combination with nivolumab 360 mg every 3 weeks showed notable antitumor activity as second-line therapy for SCLC; no new safety signals were observed compared with either agent as monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This phase II part of a phase Ib\/II study assessed liposomal eribulin (E7389-LF) plus nivolumab in 34 patients with pretreated SCLC; 8 of 33 evaluable patients (including 6\/27 pretreated with ICIs) had objective responses. The combination was tolerable; increases in vasculature-related biomarkers tended to correlate with responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0313","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T13:47:55Z","timestamp":1704462475000},"page":"226-235","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-4165","authenticated-orcid":true,"given":"Makoto","family":"Nishio","sequence":"first","affiliation":[{"name":"1Department of Thoracic Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5104-5493","authenticated-orcid":true,"given":"Shuji","family":"Murakami","sequence":"additional","affiliation":[{"name":"2Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-4850","authenticated-orcid":true,"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[{"name":"3Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6348-1302","authenticated-orcid":true,"given":"Kyoichi","family":"Okishio","sequence":"additional","affiliation":[{"name":"4Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-3092","authenticated-orcid":true,"given":"Motohiro","family":"Tamiya","sequence":"additional","affiliation":[{"name":"5Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-8063","authenticated-orcid":true,"given":"Haruki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"6Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0615-3000","authenticated-orcid":true,"given":"Daichi","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"7Internal Medicine III, Wakayama Medical University Hospital, Wakayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3427-4558","authenticated-orcid":true,"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[{"name":"8Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8432-8975","authenticated-orcid":true,"given":"Toshiyuki","family":"Kozuki","sequence":"additional","affiliation":[{"name":"9Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-6031","authenticated-orcid":true,"given":"Yuko","family":"Oya","sequence":"additional","affiliation":[{"name":"10Department of Respiratory Medicine, Fujita Health University Hospital, Toyoake, Japan. Previous Affiliation: Aichi Cancer Center, Nagoya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-4859","authenticated-orcid":true,"given":"Hiroki","family":"Izumi","sequence":"additional","affiliation":[{"name":"11Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-9428","authenticated-orcid":true,"given":"Takayuki","family":"Shiroyama","sequence":"additional","affiliation":[{"name":"12Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0613-9487","authenticated-orcid":true,"given":"Miyako","family":"Satouchi","sequence":"additional","affiliation":[{"name":"13Thoracic Oncology, Hyogo Cancer Center, Hyogo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":true,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"14Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4436-6027","authenticated-orcid":true,"given":"Shota","family":"Kaname","sequence":"additional","affiliation":[{"name":"15Oncology Early Clinical Operation II, Ono Pharmaceutical Co., Ltd., Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8250-7603","authenticated-orcid":true,"given":"Daiko","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"16Japan and Asia Clinical Development Department, Oncology, Clinical Evidence Generation Fulfillment, Deep Human Biology Learning, Eisai Co., Ltd., Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5056-403X","authenticated-orcid":true,"given":"Yohei","family":"Otake","sequence":"additional","affiliation":[{"name":"16Japan and Asia Clinical Development Department, Oncology, Clinical Evidence Generation Fulfillment, Deep Human Biology Learning, Eisai Co., Ltd., Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4556-5035","authenticated-orcid":true,"given":"Takao","family":"Takase","sequence":"additional","affiliation":[{"name":"17Clinical Data Science Department, Clinical Evidence Generation Fulfillment, Deep Human Biology Learning, Eisai Co., Ltd., Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0432-1138","authenticated-orcid":true,"given":"Taro","family":"Semba","sequence":"additional","affiliation":[{"name":"18Molecular Profiling Department, Discovery Concept Validation function, Deep Human Biology Learning, Eisai Co., Ltd., Ibaraki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5040-5856","authenticated-orcid":true,"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[{"name":"19Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"2024012914021467700_bib1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/cas.14368","article-title":"A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients","volume":"111","author":"Sekine","year":"2020","journal-title":"Cancer Sci"},{"key":"2024012914021467700_bib2","article-title":"Hycamtin (topotecan) [prescribing information]","author":"Novartis Pharmaceuticals Corporation","year":"2019"},{"key":"2024012914021467700_bib3","article-title":"Calsed (amrubicin) [prescribing information]","author":"Nippon Kayaku Co","year":"2022"},{"key":"2024012914021467700_bib4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann Oncol"},{"key":"2024012914021467700_bib5","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1158\/1538-7445.AM2019-4089","article-title":"Antitumor activity of eribulin in combination with anti-PD1 antibody in a mouse syngeneic breast cancer model","volume":"79","author":"Semba","year":"2019","journal-title":"Cancer Res"},{"key":"2024012914021467700_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2013.01.010","article-title":"Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice","volume":"443","author":"Yu","year":"2013","journal-title":"Int J Pharm"},{"key":"2024012914021467700_bib7","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/1078-0432.CCR-21-3518","article-title":"Dose escalation data from the phase 1 study of the liposomal formulation of eribulin (E7389-LF) in Japanese patients with advanced solid tumors","volume":"28","author":"Sato","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024012914021467700_bib8","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/cam4.4996","article-title":"Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer","volume":"12","author":"Udagawa","year":"2023","journal-title":"Cancer Med"},{"key":"2024012914021467700_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1535-7163.MCT-22-0475","article-title":"Liposome-encapsulated eribulin shows enhanced antitumor activity over eribulin for combination therapy with anti-PD-1 antibody","volume":"22","author":"Niwa","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2024012914021467700_bib10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1158\/2767-9764.CRC-22-0401","article-title":"Phase 1b\/II study of a liposomal formulation of eribulin (E7389-LF) plus nivolumab in patients with advanced solid tumors: results from phase 1b","volume":"3","author":"Ida","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2024012914021467700_bib11","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J Clin Oncol"},{"key":"2024012914021467700_bib12","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024012914021467700_bib13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"2024012914021467700_bib14","article-title":"Zepzelca (lurbinectedin) [prescribing information]","author":"Jazz Pharmaceuticals, Inc","year":"2022"},{"key":"2024012914021467700_bib15","article-title":"Halaven (eribulin mesylate) [prescribing information]","author":"Eisai Co., Ltd","year":"2022"},{"key":"2024012914021467700_bib16","article-title":"Opdivo (nivolumab) [prescribing information]","author":"Bristol-Myers Squibb Company","year":"2023"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0313\/3398786\/crc-23-0313.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/1\/226\/3408550\/crc-23-0313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/1\/226\/3408550\/crc-23-0313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T09:02:35Z","timestamp":1706518955000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/1\/226\/733779\/Phase-II-Study-of-the-Liposomal-Formulation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,29]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0313","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.25103032.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103035.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103041.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103038.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103068","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103038","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103050.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103047.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103044.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103032","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103056","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103044","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103050","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103074","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103053.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103062","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103059.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103056.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103029","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103065.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103062.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103047","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103035","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103059","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103068.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103065","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103053","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103071.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103071","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103041","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103029.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.25103074.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7047874","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.7047874.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]}}}